Novavax (NVAX)
(Delayed Data from NSDQ)
$11.78 USD
-0.79 (-6.28%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $11.80 +0.02 (0.17%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
NVAX 11.78 -0.79(-6.28%)
Will NVAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NVAX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVAX
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates
NVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
Other News for NVAX
Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 3
Buy/Sell: Wall Street's top 10 stock calls this week
Novavax price target lowered by $4 at B. Riley, here's why
Buy Rating for Novavax Amid Anticipated Success of COVID-Influenza Program and Market Positioning
Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024